Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA on labeling

This article was originally published in The Tan Sheet

Executive Summary

Under the Food, Drug & Cosmetic Act "'labeling' is not limited to labels on the immediate containers for your products," FDA reminds Osceola, Wisc.-based supplement marketer NeuroScience. Claims in brochures on weight control, attention deficit hyperactivity disorder and depression position the firm's products as unapproved new drugs, FDA says in an Oct. 11 letter. Claims cited by the agency include, "neurotransmitter imbalances can trigger ADHD" and "if an imbalance is detected, the technical staff at NeuroScience works with your healthcare provider to develop a Targeted Amino Acid Therapy protocol to address the imbalance." FDA sent a letter to Xango Sept. 20 regarding claims made in third-party brochures for XanGo mangosteen juice (1"The Tan Sheet" Oct. 9, 2006, p. 12)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts